Where does evidence conflict on the benefit of chromoendoscopy versus white-light endoscopy for detecting dysplasia in UC

What is known

- A meta-analysis of six studies (1277 patients) found a 7% per-patient dysplasia yield difference favoring chromoendoscopy over white-light endoscopy, with a number needed to treat of 14.3. ¹ - A large retrospective study found dye chromoendoscopy did not increase dysplasia detection compared with white-light endoscopy using targeted or random biopsies, contradicting the SCENIC consensus that named DCE the most sensitive modality. ² - Against high-definition white light the advantage narrows: in a 454-patient surveillance cohort, neoplasia was detected in similar proportions when targeted biopsies were taken by high-definition colonoscopy (17.2%), virtual chromoendoscopy (16.7%), or dye chromoendoscopy (29.2%), p=0.06. ² - The white-light comparator itself matters: a study comparing standard- with high-definition colonoscopy reported a three-fold higher dysplasia yield with the high-definition endoscope, and the SCENIC consensus favors high-definition over standard-definition white light for surveillance. ³ - Two editorials questioned SCENIC because chromoendoscopy with targeted biopsies has not been shown to improve colorectal cancer mortality. ³

What is unknown / caveats

- Meta-analyses/older RCTs favor chromoendoscopy vs a large retrospective study showing no benefit - Benefit vs standard-definition white light largely attenuates when compared against high-definition white light - Whether any detection difference translates to reduced colorectal cancer mortality remains unresolved - Chromoendoscopy is operator-dependent, time-consuming, and images degrade with active inflammation or post-inflammatory polyps - The magnitude and clinical significance of any chromoendoscopy advantage remain uncertain and depend heavily on the white-light comparator (standard- vs high-definition).

## References

1. Bharadwaj S, Narula N, Tandon P, Yaghoobi M. Role of endoscopy in inflammatory bowel disease. Gastroenterol Rep (Oxf). 2018;6(2):75-82. PMID: 29780594.

2. Gasia MF, Ghosh S, Panaccione R, Ferraz JG, Kaplan GG, Leung Y, Novak KL, Seow CH, Iacucci M. Targeted Biopsies Identify Larger Proportions of Patients With Colonic Neoplasia Undergoing High-Definition Colonoscopy, Dye Chromoendoscopy, or Electronic Virtual Chromoendoscopy. Clin Gastroenterol Hepatol. 2016;14(5):704-12.e4. PMID: 26804384.

3. Galanopoulos M, Tsoukali E, Gkeros F, Vraka M, Karampekos G, Matzaris GJ. Screening and surveillance methods for dysplasia in inflammatory bowel disease patients: Where do we stand?. World J Gastrointest Endosc. 2018;10(10):250-258. PMID: 30364842.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

---

_Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct._